Since heart disease is the world’s #1 leading cause of death, it’s no surprise when an AI company working to solve it gets a “Strong Buy” rating from analysts—and a 270% 1-year growth target.

For decades, millions with heart disease have gone undiagnosed because effective heart diagnostics are expensive and require cardiologists. But this company is bridging the gap. Their AI-ECG, developed with Mount Sinai, brings specialist-grade insights to routine frontline exams so issues will be caught faster and more affordably by frontline doctors. 

And they’re hitting several major milestones as we speak:

• First commercial customer for their software platform, a cardiology center providing services to the UK’s NHS, one of the largest healthcare networks in the world
  
  
• FDA Breakthrough Device Designation, providing priority review and a faster path to market
  
  
• New foundational U.S. patent issued, bringing the total to 44 granted patents and further protecting their AI-ECG technology from competitors
  
  
• FDA submission for their device expected for summer 2025

While they’re already public, investors have an opportunity not available on the public exchange: $3.50 units that include 1 share of convertible preferred stock + 1 warrant. 

Learn more and invest today.